- Delic Holdings Corp is a leader in new medicines and treatments for a modern world, with a business network which includes psychedelic wellness clinics, a licensed psilocybin research lab, a famed psychedelic wellness event, and dedicated media platforms
- The company announced that its co-founder and CEO, Matt Stang, presented at the H.C. Wainwright Bioconnect Virtual Conference on January 10-13, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, has long been known for its role as a trailblazer in improving access to health benefits across the country and reframing the conversation on psychedelics.
Delic announced that the Company’s Co-founder and Chief Executive Officer, Matt Stang, presented at the H.C. Wainwright Bioconnect Virtual Conference, held in an entirely virtual format from January 10-13, 2022. In addition to carrying out one-on-one meetings throughout the course of the conference, Mr. Stang made a corporate presentation on Delic Corp’s expansion strategy and overall industry outlook for the general public.
H.C. Wainwright & Co., a full-service investment bank dedicated to providing investment banking, equity research, sales and trading, as well corporate access and strategic advisory services, celebrated 150 years of service in 2018. The firm has gained a well-deserved reputation for its innovative conference line-up over the years, having recently hosted events on topics as varied and diverse as psychedelics, mining, precision oncology, hepatitis B, ophthalmology, cryptocurrencies, blockchain technology and applications, and many more. The H.C. Wainwright Bioconnect Conference, hosted by former FDA commissioner Dr Scott Gottlieb, has sought to bring together a carefully curated collection of cutting-edge biopharmaceutical firms alongside institutional investors, private equity firms, venture capitalists, and industry executives.
According to the National Institute of Mental Health, over 17 million Americans have at least one major depressive episode every year, and up to 30% of them receive insufficient help from current medical treatments. Meanwhile, a further estimated 40 million adults struggle with anxiety disorders. In a move towards addressing the growing health crisis in 2018, the FDA moved towards granting psilocybin “breakthrough therapy” status for the treatment of severe depression. Shortly thereafter, first Denver and then Oakland voted to decriminalize the use of psilocybin mushrooms, with the state of California currently reviewing a bill to decriminalize a wide variety of psychedelics (https://ibn.fm/Bu2g4).
With the sector on the cusp of broad-based legalization, the psychedelic wellness market is now projected to grow to a size of $10.75 billion by 2027, up from $4.75 billion in 2020 with a forecast CAGR of 12.36 percent over the period of 2021-2027 (https://ibn.fm/jFEPL). Delic has sought to capitalize on the sector’s growth as well as rising demand for psychedelic products and services through the expansion of its proprietary Ketamine Wellness Centers (“KWC”), the largest chain of psychedelic wellness clinics in the country, with 15 more clinics opening in the next 18 months. Delic has also looked to expand its footprint within the sector through its other related businesses, which include Delic Labs, the sole entity currently licensed by Health Canada to focus exclusively on research and development of psilocybin vaporization technology; Meet Delic, the world’s largest psychedelic wellness event; as well as media platforms, Reality Sandwich and Delic Radio.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF